IL1B and breast carcinoma: HABQ treatment resulted in decreased hepatic level of inflammatory cytokines such as IL‐1 and IL‐6, and decreased level of protumor cytokines such as IL‐1b, IL‐6, and IL‐8 in cancer tissue, indicating both anti‐inflammatory and tumor‐inhibiting properties.[342] Almeida et al developed an undecylenic acid‐modified thermally hydrocarbonized porous silicon nanocarrier covalently conjugated to a synthesized amide‐modified HA‐derived polymer (UnTHCPSi‐HA+) to target breast cancer.